The global lung cancer therapeutics market is anticipated to grow at a CAGR of 8.7% during the forecast period (2021-2027). The key factor to drive the market growth is the rising number of smokers in various countries that is the leading risk factor for lung cancer. According to the American Cancer Society, smoking is thought to be responsible for approximately 80% of lung cancer deaths, and this estimate is likely to be even higher in the case of small cell lung cancer (SCLC). Furthermore, according to Macmillan Cancer Support, tobacco use is the leading cause of lung cancer and the leading risk factor. This includes using tobacco products such as cigars, cigarettes, and others. The more you smoke, the greater the risk is associated. Smoker or ex-smokers account for approximately 9 out of 10 lung cancer cases (90%). Moreover, people who do not smoke can also develop lung cancer, but their chances are much lower. One out of every 10 people who develop lung cancer (10%) has never smoked.
A full report of Lung Cancer Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/lung-cancer-therapeutics-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in January 2019, Eli Lilly and Co announced that that the U.S. Food and Drug Administration (FDA) has approved its new indication for ALIMTA that is in combination with KEYTRUDA, produced and commercialized by Merck and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) that have no ALK genomic tumor aberrations. This new indication demonstrates Lilly’s ongoing commitment to providing effective treatment options that can make a significant difference in the lives of people living with lung cancer.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-therapeutics-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Drugs
o By Therapy
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Lung Cancer Therapeutics Market Report Segment
By Drugs
- Platinol
- Taxol
- Gemzar
- Alimta
- Others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori)
By Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Others
By End-User
- Multispeciality Hospitals
- Cancer Research Centers
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
